Neurogene Inc (NGNE) Stock Price, Quote & News

Latest News on NGNE

Nov 28, 2024, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out

Nov 27, 2024, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation

Nov 26, 2024, 10:00 AM EST - 7 weeks ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Nov 25, 2024, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation

Nov 24, 2024, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect

Nov 22, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation

Nov 20, 2024, 10:00 AM EST - 2 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 18, 2024, 5:25 PM EST - 2 months ago

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Nov 18, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect

Nov 18, 2024, 6:45 AM EST - 2 months ago

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 17, 2024, 10:00 AM EST - 2 months ago

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 15, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation

Nov 14, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation

Nov 13, 2024, 11:30 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out

Nov 12, 2024, 11:25 AM EST - 2 months ago

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Nov 11, 2024, 4:01 PM EST - 2 months ago

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 4, 2024, 7:30 AM EST - 2 months ago

Neurogene Announces Oversubscribed $200 Million Private Placement

Oct 21, 2024, 7:30 AM EDT - 3 months ago

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Aug 9, 2024, 7:30 AM EDT - 5 months ago

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Aug 7, 2024, 7:30 AM EDT - 5 months ago

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Jul 2, 2024, 7:30 AM EDT - 7 months ago

Neurogene to Participate in BMO Genetic Medicines Summit

Jul 1, 2024, 7:30 AM EDT - 7 months ago

Neurogene Announces Addition to Russell 3000® Index

Jun 18, 2024, 9:26 AM EDT - 7 months ago

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Jun 5, 2024, 7:30 AM EDT - 8 months ago

Neurogene to Participate in Upcoming Conferences

Jun 3, 2024, 7:30 AM EDT - 8 months ago

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

May 10, 2024, 7:30 AM EDT - 9 months ago

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

May 7, 2024, 6:19 AM EDT - 9 months ago

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

Apr 22, 2024, 4:36 PM EDT - 9 months ago

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

Mar 18, 2024, 4:14 PM EDT - 10 months ago

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Mar 4, 2024, 7:30 AM EST - 11 months ago

Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

Feb 29, 2024, 7:30 AM EST - 11 months ago

Neurogene to Participate in Upcoming Investor Conferences

Jan 16, 2024, 7:00 AM EST - 1 year ago

Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Jan 5, 2024, 7:00 AM EST - 1 year ago

Neurogene Announces Business Update and 2024 Outlook

Dec 19, 2023, 7:00 AM EST - 1 year ago

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

Dec 14, 2023, 7:00 PM EST - 1 year ago

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

Sep 22, 2023, 8:00 AM EDT - 1 year ago

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

Jul 25, 2023, 10:49 AM EDT - 1 year ago

NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX

Jul 18, 2023, 6:30 AM EDT - 1 year ago

Neurogene and Neoleukin Announce Definitive Merger Agreement

Apr 19, 2023, 4:04 AM EDT - 1 year ago

Market Cap	261.89M
Revenue (ttm)	0.00
Net Income (ttm)	-36.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	159,300
Avg Vol	467,654
Day's Range	N/A - N/A
Shares Out	14.86M
Stochastic %K	2%
Beta	1.12
Analysts	Strong Sell
Price Target	$52.80